US Patent

US8216560 — Ion binding polymers and uses thereof

Method of Use · Assigned to Relypsa Inc · Expires 2027-03-14 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating ion imbalances, including hyperkalemia caused by renal failure or certain medications.

USPTO Abstract

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1766 — patiromer-sorbitex-calcium
U-1766 — patiromer-sorbitex-calcium
U-1766 — patiromer-sorbitex-calcium
U-1766 — patiromer-sorbitex-calcium

Patent Metadata

Patent number
US8216560
Jurisdiction
US
Classification
Method of Use
Expires
2027-03-14
Drug substance claim
No
Drug product claim
No
Assignee
Relypsa Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.